Consensus statement of the Spanish Society of Internal Medicine and the Spanish Society of Medical Oncology on secondary thromboprophylaxis in patients with cancer
Clin. transl. oncol. (Print)
; 23(4): 697-708, abr. 2021.
Article
en En
| IBECS
| ID: ibc-220905
Biblioteca responsable:
ES1.1
Ubicación: ES15.1 - BNCS
ABSTRACT
Up to 20% of cancer patients will develop some manifestation of venous thromboembolic disease (VTD) during their clinical course. VTD greatly impacts morbidity, mortality, quality of life and pharmaceutical expenditure. In addition, both thrombotic relapse and major haemorrhages derived from VTD treatment are more likely in oncological patients. To make the decision to establish secondary thromboprophylaxis as an indefinite treatment in these patients, it is important to review all the risk factors involved, whether related to the disease, the patient or the prior thrombotic event. The objectives of this consensus of the Spanish Society of Internal Medicine (Sociedad Española de Medicina InternaSEMI) and the Spanish Society of Medical Oncology (Sociedad Española de Oncología MédicaSEOM) are to establish recommendations that help assess the risk of recurrence of VTD and haemorrhagic risk in patients with cancer, as well as to analyse the evidence that exists on the currently available drugs, which will allow the establishment of a protocol for shared decision-making with the informed patient (AU)
Palabras clave
Texto completo:
1
Colección:
06-national
/
ES
Base de datos:
IBECS
Asunto principal:
Inhibidores del Factor Xa
/
Hemorragia
/
Neoplasias
Límite:
Humans
País/Región como asunto:
Europa
Idioma:
En
Revista:
Clin. transl. oncol. (Print)
Año:
2021
Tipo del documento:
Article